New Migraine Prevention Drug Approved in Japan: Injection Once Every Three Months Helps Suppress Attacks
Published
Pharmaceutical company Lundbeck Japan announced on September 16, 2026, that it had obtained approval in Japan for the manufacture and sale of eptinezumab, a drug that suppresses the occurrence of migraine attacks.
Migraine is a disease in which throbbing, severe pain recurs repeatedly. When the pain is intense, it can have a significant impact on daily life, including work, study, and housework. Until now, treatment has centered on relieving pain with medication when a headache occurs.
Eptinezumab is a preventive drug that works to make the attacks themselves less likely to occur. Because it can be given as an injection once every three months, patients do not need to take medication every day. It is expected to help reduce the burden on patients.
On the other hand, the effects and side effects of preventive drugs vary from person to person. It is important to decide whether to use them after thorough consultation with a doctor.
With this approval, the treatment options for people suffering from migraine have increased. Attention is now focused on how the drug will be used in actual medical settings.
Sources: 家庭画報
More Japan news
- Toyota, Nissan and Honda to Hold Engineer Event in Fiscal 2026 Under the Theme of “AI”
- HTC NIPPON Promotes Business Use of the Smart Glasses "VIVE Eagle" as Sponsor of Remote Guidance App Exhibition
- Defense-Related ETF "GX Defense Tech" Publishes Stock Price Information; Detailed News Not Available
- U.S. Ambassador to South Korea Marks 100 Days in Office, Stresses the Importance of Protecting Trust Between South Korea and the United States
- South Korean National Assembly Passes Special Counsel Act to Investigate "Fabricated Indictments"
- Former Professor Embroiled in Stem Cell Paper Fabrication Scandal Acquires UAE Citizenship, Loses South Korean Nationality
- Foreign Minister Motegi Holds Talks with Foreign Ministers of France, Italy and the UK, Calls for Appropriate Response on EU Exclusion of Japanese-Made EVs from Preferential Treatment
- Health Drink Market in Japan Set to Grow, Driven by Aging Population and Health Consciousness